Catherine Belle Meador, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 16 | 2023 | 13019 | 1.120 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2020 | 5163 | 0.820 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 268 | 0.740 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 5 | 2023 | 5171 | 0.720 |
Why?
|
Leadership | 2 | 2016 | 1357 | 0.570 |
Why?
|
Small Cell Lung Carcinoma | 4 | 2023 | 384 | 0.560 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 5522 | 0.520 |
Why?
|
Molecular Targeted Therapy | 3 | 2020 | 2723 | 0.520 |
Why?
|
Genotype | 3 | 2021 | 12946 | 0.510 |
Why?
|
Antineoplastic Agents | 6 | 2021 | 13655 | 0.460 |
Why?
|
Biomedical Research | 2 | 2016 | 3306 | 0.370 |
Why?
|
Mutation | 11 | 2023 | 29717 | 0.330 |
Why?
|
MAP Kinase Signaling System | 2 | 2015 | 1525 | 0.330 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2015 | 2028 | 0.310 |
Why?
|
Acrylamides | 3 | 2017 | 252 | 0.260 |
Why?
|
Negotiating | 2 | 2016 | 133 | 0.250 |
Why?
|
Neoplasms | 4 | 2023 | 21596 | 0.250 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2283 | 0.240 |
Why?
|
Education, Medical | 1 | 2016 | 1717 | 0.230 |
Why?
|
Aniline Compounds | 3 | 2017 | 983 | 0.210 |
Why?
|
Career Choice | 2 | 2016 | 743 | 0.180 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2019 | 23 | 0.170 |
Why?
|
Biology | 1 | 2021 | 292 | 0.170 |
Why?
|
Genetic Variation | 1 | 2014 | 6540 | 0.160 |
Why?
|
Quinazolines | 2 | 2015 | 1355 | 0.160 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 246 | 0.150 |
Why?
|
Tumor Microenvironment | 2 | 2020 | 3564 | 0.150 |
Why?
|
Mice, Nude | 4 | 2017 | 3689 | 0.140 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2017 | 182 | 0.140 |
Why?
|
Receptor, EphA2 | 1 | 2016 | 42 | 0.140 |
Why?
|
Exons | 1 | 2021 | 2431 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6754 | 0.130 |
Why?
|
Group Processes | 1 | 2016 | 225 | 0.120 |
Why?
|
src-Family Kinases | 1 | 2017 | 551 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 416 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.110 |
Why?
|
Curriculum | 2 | 2016 | 3589 | 0.110 |
Why?
|
Humans | 22 | 2023 | 742088 | 0.110 |
Why?
|
Professional Competence | 1 | 2016 | 448 | 0.110 |
Why?
|
INDEL Mutation | 1 | 2013 | 279 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1380 | 0.100 |
Why?
|
Cell Line, Tumor | 6 | 2023 | 16665 | 0.100 |
Why?
|
Cell Lineage | 1 | 2020 | 2504 | 0.100 |
Why?
|
Benzamides | 1 | 2016 | 1378 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1758 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2749 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11472 | 0.070 |
Why?
|
Piperazines | 1 | 2017 | 2488 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1659 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2015 | 2455 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14720 | 0.070 |
Why?
|
Animals | 8 | 2023 | 168561 | 0.070 |
Why?
|
Genome, Human | 2 | 2015 | 4420 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3151 | 0.060 |
Why?
|
Octamer Transcription Factors | 1 | 2023 | 23 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2014 | 2940 | 0.060 |
Why?
|
Biopsy | 1 | 2015 | 6756 | 0.060 |
Why?
|
Lactates | 1 | 2023 | 432 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5133 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 10472 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2017 | 9185 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3439 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2020 | 62966 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 902 | 0.040 |
Why?
|
Genomics | 1 | 2014 | 5692 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6347 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 1114 | 0.040 |
Why?
|
Pneumonectomy | 1 | 2023 | 1093 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 10856 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5462 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2023 | 3471 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12773 | 0.030 |
Why?
|
Mice | 5 | 2023 | 81045 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 731 | 0.030 |
Why?
|
Aged | 4 | 2019 | 162944 | 0.030 |
Why?
|
Drug Synergism | 1 | 2016 | 1791 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8621 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1372 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2015 | 848 | 0.020 |
Why?
|
ras Proteins | 1 | 2015 | 1060 | 0.020 |
Why?
|
Transfection | 1 | 2017 | 5892 | 0.020 |
Why?
|
Signal Transduction | 3 | 2017 | 23387 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2023 | 11001 | 0.020 |
Why?
|
Macrophages | 1 | 2023 | 5655 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 77098 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1683 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2495 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1794 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2023 | 8425 | 0.020 |
Why?
|
Male | 4 | 2019 | 349538 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9305 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3111 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6483 | 0.020 |
Why?
|
Lung | 1 | 2023 | 9826 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 1940 | 0.020 |
Why?
|
Transcription Factors | 1 | 2023 | 12164 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 57683 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4801 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 13921 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2013 | 3585 | 0.010 |
Why?
|
Middle Aged | 3 | 2019 | 213127 | 0.010 |
Why?
|
Female | 4 | 2019 | 379592 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9715 | 0.010 |
Why?
|
Prognosis | 1 | 2019 | 29010 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 23320 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 40054 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2017 | 39004 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15494 | 0.010 |
Why?
|
Prospective Studies | 1 | 2017 | 53187 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 72145 | 0.010 |
Why?
|
Adult | 1 | 2017 | 213712 | 0.000 |
Why?
|